AACR 2023 | Clostridium novyi-NT with checkpoint blockade in solid tumors

Blessie Elizabeth Nelson, MBBS, DMRT, The University of Texas MD Anderson Cancer Center, Houston, TX, provides an overview of a Phase I trial (NCT03435952) of Clostridium novyi-NT (non-toxic) with pembrolizumab in patients with solid tumors. Clostridium novyi-NT is an attenuated form of C. novyi, which has shown to have antitumor properties. The study demonstrated promising clinical activity in patients irrespective of tumor type. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.